secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001213900-25-042962
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex completes Phase 2 dosing of IHL-42X for OSA; topline data expected July 2025
--------------------------------------------------------------------------------

- Completed patient dosing in Phase 2 portion of RePOSA study on May 8, 2025; end-of-study follow-up by May 17, 2025.
- Topline results from Phase 2 expected in July 2025; end-of-Phase 2 FDA meeting to follow.
- Phase 3 plan: 440 patients exclusively at U.S. sites; decision supported by site and patient enthusiasm.
- Incannex engaged in preliminary commercial discussions for IHL-42X ahead of data readout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025042962/0001213900-25-042962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025042962/ea0242110-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer